References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAssessment of quality of life in patients undergoing total joint replacement for OA of the lower limb
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 693

Detailed reference viewed: 43 (10 ULg)
Full Text
Peer Reviewed
See detailTrends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007)
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, Dominique et al

in Arthritis Care & Research (2012), 64(5), 744-750

Detailed reference viewed: 37 (18 ULg)
Full Text
Peer Reviewed
See detailEfficacy of a strontium ranelate 2 G/vitamin D3 1000 UI combination on the correction of vitamin D insufficiency
Rizzoli, R; Dawson-Hughes, B; Kaufman, JM et al

in Osteoporosis International (2012, May), 23(S2), 225

Detailed reference viewed: 47 (5 ULg)
Full Text
Peer Reviewed
See detailHealth claims assessment in the field of joint and cartilage: a consensus viewpoint of the Group for the Respect of Ethics and Excellence in Science
Bruyère, Olivier ULg; Avouac, Bernard; Richette, Pascal et al

in Current Medical Research & Opinion (2012), 28(4), 611-6

Abstract Introduction: In 2006, the European Parliament and Council issued a regulation (No. 1924/2006) for the nutrition and health claims made on foods, including food supplements. According to the ... [more ▼]

Abstract Introduction: In 2006, the European Parliament and Council issued a regulation (No. 1924/2006) for the nutrition and health claims made on foods, including food supplements. According to the regulation, the use of nutrition and health claims shall only be permitted if the substance in respect of which the claim is made has been shown to have a beneficial nutritional or physiological effect. In the field of joint and cartilage health, there is no clear scientific-based definition of the nature of such a beneficial nutritional or physiological effect. The objective of this paper is to scientifically define the possible content of health claims related to joint and cartilage health and to provide scientific guidelines for the design of clinical studies which need to be adopted to substantiate such health claims. Methods: Literature review up to September 2011 followed by a consensus expert discussion organized by the Group for the Respect of Ethics and Excellence in Science (GREES). Results: In line with the general principles of the PASSCLAIM and the Codex recommendations, the GREES identified four acceptable health claims related to joint and cartilage health based on the effects on discomfort, joint and cartilage structural integrity or risk factors for joint and cartilage diseases. The GREES considers that randomized controlled trials on a relevant outcome is the best design to assess health claims. Moreover, animal studies could also be of interest to substantiate some health claims, to assess the clinical relevance of endpoints used in human studies or to extrapolate data obtained in patients to the target (apparently) healthy population. Conclusion: According to the methodology and biomarkers used in the study and whether or not additional animal studies are provided to support the claim, various health claims can be acceptable in the field of joint and cartilage health. [less ▲]

Detailed reference viewed: 22 (6 ULg)
Full Text
Peer Reviewed
See detailSeverity of incident vertebral fracture and future fracture risk: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 60-61

Detailed reference viewed: 27 (9 ULg)
Full Text
Peer Reviewed
See detailIndirect comparison of bazedoxifene vs. oral bisphosphonates for the prevention of nonvertebral fractures in high-risk postmenopausal osteoporosis population
Ellis, A; Jansen, J; Luo, X et al

in Osteoporosis International (2012, March), 23(S2), 64-65

Detailed reference viewed: 37 (2 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension
Papapoulos, S; Brown, JP; Chapurlat, R et al

in Osteoporosis International (2012, March), 23(S2), 76

Detailed reference viewed: 78 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone
Boonen, S; Reginster, Jean-Yves ULg; Kaufman, JM et al

in Osteoporosis International (2012, March), 23(S2), 79-80

Detailed reference viewed: 43 (2 ULg)
Full Text
Peer Reviewed
See detailWhat are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Osteoporosis International (2012, March), 23(S2), 81-82

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailStructure modifying effects of strontium ranelate in knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiaensen, C et al

in Osteoporosis International (2012, March), 23(S2), 58-59

Detailed reference viewed: 119 (5 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiansen, C et al

in Osteoporosis International (2012, March), 23(S2), 366-367

Detailed reference viewed: 43 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate and risk of venous thromboembolism (VTE) : an update of a retrospective cohort study in the UK general practice research database (GPRD)
Cooper, C; Deltour, N; Speirs, C et al

in Osteoporosis International (2012, March), 23(S2), 364-365

Detailed reference viewed: 63 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate uncouples bone formation from bone resorption in male osteoporotic patients
COLLETTE, Julien ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2012, March), 23(S2), 365-366

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge and use by general practitioners of Belgium of the FRAX tool
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 363-364

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailEffect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study
Bruyère, Olivier ULg; Zegels, Brigitte ULg; LEONORI, Lorenzo ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 362-363

Detailed reference viewed: 41 (8 ULg)
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Detailed reference viewed: 16 (5 ULg)